Kelly E. McCann, MD, PhD

Kelly E. McCann, MD, PhD, is an assistant professor and breast medical oncologist at UCLA.

Articles

Unmet Needs and Future Outlook for HER2-Targeted Therapies

December 4th 2025

Panelists discuss how innovative HER2-targeted strategies and precision approaches will define the next era of breast cancer therapy.

Exciting New Data for TNBC Therapies

December 4th 2025

Panelists discuss how new trial results from ASCENT-03 and TROPION-Breast02 are shaping next-generation TNBC therapies.

Disease State Information on TNBC

November 25th 2025

Panelists discuss how molecular characterization and novel agents are redefining the management of TNBC.

Treatment of HER2-Low and Future Therapies in Metastatic Breast Cancer

November 25th 2025

Panelists discuss how HER2-low and HER3-directed therapies are expanding precision treatment opportunities in metastatic breast cancer.

Additional Data with HER2-Targeted Agents in Metastatic Breast Cancer

November 18th 2025

Panelists discuss how newer HER2-targeted therapies show promise for CNS disease control and broader metastatic management.

Treatment Sequencing in Later Lines of Therapy in HER2+ Metastatic Breast Cancer

November 18th 2025

Panelists discuss how thoughtful sequencing of HER2-targeted agents maximizes benefit and extends survival in metastatic settings.

First-Line Treatment Regimens in Metastatic HER2+ Breast Cancer

November 11th 2025

Panelists discuss how evolving first-line HER2-targeted combinations are improving outcomes and redefining standards in metastatic breast cancer..

The Role of ADCs in Different Subgroups

November 11th 2025

Panelists discuss how ADCs are revolutionizing HER2-targeted therapy through precision delivery and improved tolerability across patient subgroups.

Clinical Trial Evidence for HER2-Targeted Therapies in Early Breast Cancer

November 3rd 2025

Panelists discuss how new trial data are optimizing early-stage HER2-positive breast cancer treatment through refined, evidence-based regimens.

Background Information on Targeted Therapies in Breast Cancer

November 3rd 2025

Panelists discuss how the evolution of HER2 testing and classification has redefined treatment strategies and expanded therapeutic opportunities in breast cancer.

Dr McCann on the Potential Clinical Utility of Gedatolisib in Advanced Breast Cancer

October 31st 2025

Kelly E. McCann, MD, PhD, discusses findings from the VIKTORIA-1 trial of gedatolisib-based regimens in hormone receptor–positive advanced breast cancer.

Dr McCann on the Importance of Integrating Patient Preferences Into Treatment Planning for Patients With HER2+ Breast Cancer

August 25th 2025

Kelly McCann, MD, PhD, discusses the relevance of patient preferences during treatment decision-making for patients with HER2-positive breast cancer.

HER2-Negative and HER2-Low mBC: Key Takeaways

July 28th 2025

Panelists discuss how the field has made exciting strides, with oral selective estrogen receptor degraders (SERDs) likely moving into early-stage disease and the need for alternative antibody-drug conjugate (ADC) payloads beyond topoisomerase I inhibitors to overcome resistance mechanisms.

Defining HER2-Low and -Ultralow Expression: Practical Challenges and Solutions

July 28th 2025

Panelists discuss how HER2 testing challenges for identifying HER2-low and -ultralow expression require coordination with pathologists and may involve

Dr McCann on the Standard of Care for Managing ER+/HER2– Advanced Breast Cancer

July 23rd 2025

Kelly E. McCann, MD, PhD, details the current standard of care and novel approaches for the treatment of ER-positive, HER2-negative advanced breast cancer.

Sequencing ADCs in HER2-Low and -Ultralow mBC: Clinical Considerations and Emerging Evidence

July 21st 2025

Panelists discuss how they approach sequencing decisions for patients with hormone receptor–positive, HER2- low/ultralow disease, emphasizing selective use of trastuzumab deruxtecan in first-line chemotherapy settings while considering quality-of-life factors.

DESTINY-Breast06: Updates From Subgroup and Biomarker Analyses

July 21st 2025

Panelists discuss how subgroup analyses from DESTINY-Breast06 show trastuzumab deruxtecan benefits across different mutation groups, with particularly strong responses in patients with BRCA1/2-mutated disease due to the topoisomerase I inhibitor payload.

Navigating Treatment Selection for HER2-Low and -Ultralow Metastatic Breast Cancer

July 14th 2025

Panelists discuss how treatment options for HER2-low and HER2-ultralow metastatic breast cancer include trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan, with sequencing becoming a key consideration.

Balancing Efficacy and Safety of ADCs in HER2– Metastatic Breast Cancer

July 14th 2025

Panelists discuss how to manage toxicities associated with datopotamab deruxtecan, particularly ocular toxicity and stomatitis, using prophylactic measures such as steroid mouthwash and eye drops.

Evolving ADC Strategies in HER2– mBC: TROPION-Breast01 and Real-World Data From ASCO 2025

July 7th 2025

Panelists discuss how datopotamab deruxtecan from the TROPHY-PD-01 trial compares with sacituzumab govitecan, highlighting different toxicity profiles and the challenge of sequencing multiple antibody-drug conjugates (ADCs) with the same TROP2 payload.